In re Entresto (Sacubitril/Valsartan) Patent Litigation — Representing Teva in a patent infringement suit brought by Novartis relating to the drug Entresto®.
Boehringer Ingelheim Pharmaceuticals Inc., et al. v. [16 Defendants] — Representing Boehringer Ingelheim in Hatch-Waxman litigation arising from Defendants’ submissions of ANDAs seeking approval to manufacture and sell generic versions of Boehringer’s Jardiance® (empagliflozin) products used to treat type II diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. et al. v. Mylan Pharmaceuticals, Inc. et al. — Representing Boehringer Ingelheim in patent infringement suit arising from Defendants’ submissions of ANDAs seeking approval to manufacture and sell generic versions of Boehringer’s Tradjenta® (linagliptin) and Jentadueto® (linagliptin and metformin hydrochloride) tablets used to treat type II diabetes.
In re Namenda Indirect Purchaser Antitrust Litigation — Counsel for Allergan and Forest Laboratories in class action antitrust litigation related to the blockbuster Alzheimer’s drug Namenda.
UCB Inc., et al. v. Actavis Laboratories UT, Inc. — Represented Actavis in a patent infringement suit brought by UCB Pharma relating to patents covering rotigotine transdermal drug delivery systems (Neupro®). Bench trial resulted in the invalidation of the patent-in-suit.
Represented pharmaceutical company in arbitration regarding licensed patent estate for several blockbuster drugs.
Represented pharmaceutical company in contract dispute requiring technical analysis of immuno-oncology drug pipeline products.
Duchesnay Inc. v. Actavis Laboratories FL, Inc., et al. — Represented Actavis and Teva in a patent infringement suit regarding an ANDA covering doxylamine succinate/pyridoxine hydrochloride tablets for the treatment of morning sickness. Obtained favorable settlement.
